Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2017-02-23 Earnings Release
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
2016年度业绩快报
Earnings Release Classification · 95% confidence The document is titled '2016 年度业绩快报' which translates to '2016 Annual Performance Express Report' or '2016 Annual Earnings Quick Report'. It contains preliminary financial data for the year 2016, including revenue, profit, net income, earnings per share, and asset information. The document explicitly states that the data is preliminary, internally audited but not yet audited by an accounting firm, and may differ from the final annual report. It also includes explanations of business performance and comparisons with previous forecasts. The document length is 1475 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or a certification. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or annual financial results with key highlights only. It is not a full Annual Report (10-K) or Interim Report (IR) because it is preliminary and brief. Therefore, the correct classification is Earnings Release (ER). FY 2016
2017-02-23 Chinese
关于获得发明专利证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement about obtaining an invention patent certificate, detailing patent number, name, application date, and validity. It is a formal disclosure of intellectual property rights, not a financial report, management change, or regulatory filing related to financial performance or governance. It does not fit into categories like Annual Report, Interim Report, or Capital Update. It is a specific announcement about patent acquisition, which is a regulatory announcement but does not fall under the defined categories for financial or governance filings. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2017-02-21 Chinese
关于全资子公司获得药品临床试验批件的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company about its wholly-owned subsidiary receiving a clinical trial approval from the national drug regulatory authority. It includes a risk warning and a commitment to disclose further information as required. The document is brief (643 characters) and does not contain financial data, financial results, or detailed report content. It is an official announcement of a regulatory approval event, not a financial report or management discussion. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2017-02-06 Chinese
关于控股股东进行股票质押式回购交易的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding a stock pledge repurchase transaction by a controlling shareholder of the company. It details the number of shares pledged, the pledge start and end dates, the pledgee, and the proportion of shares pledged. It also states that the pledge does not affect control or financial status. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about a shareholder's stock pledge transaction, which fits the category of Transaction in Own Shares (POS). The document length is short and it is not a report or certification, so it is not RNS or RPA. Therefore, the best classification is POS.
2017-01-18 Chinese
关于公司内部资源整合后商誉分摊的会计处理专项说明
Regulatory Filings
2017-01-10 Chinese
关于聘任证券事务代表的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a securities affairs representative (徐少华女士) by the company's board of directors. It includes personal details, qualifications, and contact information of the appointee. There is no financial data, no mention of financial results, no regulatory certifications, or report attachments. The document is a formal announcement about a management-related change, specifically about a corporate officer appointment. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused solely on this appointment, confirming it is not a full report or other filing type.
2017-01-10 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.